CAR-TCR Summit Boston 2021
Evvnt Promotion / evvnt
Archivio
30.08.2021 - 03.09.2021 Hynes Convention Center, 900 Boylston Street, 02115 Boston, Massachusetts, USA
Time: 09:00 to 17:00
Temi della conferenza
With 2 CAR-T therapies striving for global approval, and a 3rd contender from Bristol-Myers Squibb closing in on the finish line of the race to market, the CAR-TCR field continues to boom with excitement as the competition begins to heat back up.
It is well known that the current approved therapies have encountered some difficulties, specifically around their pricing and uptake in hospitals due to expensive manufacturing processes.
With 2 CAR-T therapies striving for global approval, and a 3rd contender from Bristol-Myers Squibb closing in on the finish line of the race to market, the CAR-TCR field continues to boom with excitement as the competition begins to heat back up.
It is well known that the current approved therapies have encountered some difficulties, specifically around their pricing and uptake in hospitals due to expensive manufacturing processes.
Professional congress organizer (PCO)
Hanson Wade
Hanson Wade
Annotazioni
Brochure: https://go.evvnt.com/637810-3?pid=4832
Speakers: Sanjay Srivastava, Accenture, Robin Goodreau, Access Biologicals, Erica Elefant, Adaptimmune, Stewart Abbott, Adicet Bio, Paul Rennert, Aleta Biotherapeutics, and more.
Brochure: https://go.evvnt.com/637810-3?pid=4832
Speakers: Sanjay Srivastava, Accenture, Robin Goodreau, Access Biologicals, Erica Elefant, Adaptimmune, Stewart Abbott, Adicet Bio, Paul Rennert, Aleta Biotherapeutics, and more.
Informazioni ed Iscrizioni:
https://go.evvnt.com/637810-2?pid=4832
Ms. Georgina FitzGerald
Medicina General
Contatto organizzatori
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Noi, Going International, siamo un’azienda che si è scelta come obiettivo di rendere acessibile la formazione a una grandissima quantità di persone, oltrepassanddo i confini geografici e sociali."
